European LeukemiaNet 2020 recommendations: requirements for tyrosine kinase inhibitor discontinuation
| Mandatory . | Minimal . | Optimal . |
|---|---|---|
| CP-CML | First-line TKI or second-line TKI if motivated by intolerance to first-line drug | Duration of therapy >5 y |
| Real time quantitative polymerase chain reaction on the IS scale | Typical e13a2 or e14a2 BCR-ABL1 transcripts | DMR duration >3 y if MR4 |
| Patient motivation and adherence | Duration of therapy >5 y if imatinib >4 y if second-generation TKI | DMR duration >2 y if MR4.5 |
| DMR duration (MR4 or M4.5) >2 y |
| Mandatory . | Minimal . | Optimal . |
|---|---|---|
| CP-CML | First-line TKI or second-line TKI if motivated by intolerance to first-line drug | Duration of therapy >5 y |
| Real time quantitative polymerase chain reaction on the IS scale | Typical e13a2 or e14a2 BCR-ABL1 transcripts | DMR duration >3 y if MR4 |
| Patient motivation and adherence | Duration of therapy >5 y if imatinib >4 y if second-generation TKI | DMR duration >2 y if MR4.5 |
| DMR duration (MR4 or M4.5) >2 y |
CML, chronic myeloid leukemia; CP, chronic phase; DMR, deep molecular response; IS, internationally standardized; MR4, 4-log molecular response; MR4.5, 4.5-log molecular response; TKI, tyrosine kinase inhibitor.